Rhino Biotech Limited (RBRXF)
Stock analysis · OTC · Financial Services · Shell Companies
Rhino Biotech Limited (RBRXF) is a publicly traded company in the Financial Services sector. Latest price: $0.00. Market cap $3.10K. Trailing PE -0.17. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Proprietary Signals
About Rhino Biotech Limited
Rhino Biotech Limited is dedicated to pioneering the development of health supplements sourced from plants and fungi, in addition to biopharmaceutical solutions designed for both disease prevention and treatment. The company adopted its current name, Rhino Biotech Limited, in September 2021, having previously operated as Eurasia Energy Limited. Established in 2003, its operations are based in South Hill, Anguilla.
Valuation
| P/E (TTM) | -0.17× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | -0.06× |
| P/FCF (TTM) | -0.19× |
| EV / EBITDA | -2.03× |
| EV / Sales | 0.00× |
| Earnings Yield | -614.59% |
| Free Cash Flow Yield | -515.17% |
Fundamentals
| Enterprise Value | $43.10K |
|---|---|
| Net Income (TTM) | -$19.08K |
| Free Cash Flow (TTM) | -$16.00K |
| Net Debt | $39.99K |
| Working Capital | -$3.05K |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | 42.73% |
| Return on Invested Capital | 695.71% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap